AstraZeneca’s (LSE: AZN) Calquence (acalabrutinib) has secured a new approval in Japan, for the treatment of adults with chronic lymphocytic leukemia (CLL), in the first-line setting.
The nod for the selective Bruton’s tyrosine kinase inhibitor adds to an existing approval in CLL in the country, for relapsed or refractory CLL.
The move into the earlier treatment setting was backed by data from the Phase III ELEVATE-TN study, published in The Lancet, which showed a significant improvement in progression-free survival (PFS).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze